Denali Therapeutics (DNLI)
(Real Time Quote from BATS)
$20.59 USD
-0.18 (-0.87%)
Updated Jun 10, 2024 10:46 AM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Denali Therapeutics Inc. [DNLI]
Reports for Purchase
Showing records 121 - 140 ( 185 total )
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Consistent CSF Target Engagement Data Might Establish Pipeline Potential Across Multiple Indications
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
The Pubmed Times: Loss of C9orf72 in Microglia Leads to Complement Mediated Neurodegeneration
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
The Pubmed Times - Interplay of Astrocytic APOE4 and Microglial TREM2 in Tau-Mediated Neurodegeneration
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Follow the Biomarkers - DNLI''s Mantra for Drug Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
First, Detailed Look At DNL151 - Looking Ahead To DNL310 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
DNL310 Remains In Focus, But Pipeline Shouldn''t Be Overlooked
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Denali Pushes the Pedal on TV Platform Our Insights on the ATV:TREM2 program; Reit Buy and Raising PT to $95
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
DNL310 Continues Promise As DNLI Provides 12 Week Update at WORLD
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L